Series A · 2026-11-12 · Healthcare
Orakl Oncology raises $34.0M
71
AI Score
Amount
$34.0M
Round
Series A
Lead
Norrsken VC, Singular
HQ
Paris, FR
Why it matters: The round and the Sanofi asset deal give a concrete test of whether Orakl's 90% trial-prediction figure holds up outside a preprint.
Paris-based Orakl Oncology raised $34M in a Series A led by Norrsken VC and Singular.
- Participants:
- InfraVia, Serena, Patient Autonome Fund, Bpifrance, teampact.ventures, Plug and Play, Verve Ventures, Speedinvest, HCVC, Thomas Wolf, Stan Polu, Jacques Boitreaud
- Source:
- Tech Funding News ↗ · Midu summary
Other rounds by Orakl Oncology
Deal Dossier PRO
Pro feature
Deal Dossier for Orakl Oncology
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing